To our knowledge, our study is the first to show that cardiomyocyte specific TLR4 deletion attenuates the effects of angiotensin II on cardiac hypertrophy, fibrosis, function, and inflammation. The gene discussed is AGT; the disease is cardiac hypertrophy.